Genomic Landscape and Clinical Outcomes of Advanced Pediatric Myelodysplastic Syndromes
European Journal of Haematology · 2026-07 · 117 (1) · 235-244
DOI: 10.1111/ejh.70182 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 04.04.2026. Verfasst von Chenmeng Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Mutation, Genomics. Die Arbeit nennt 34 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
Pediatric myelodysplastic syndromes (MDS) differ from adult MDS, and their genetic basis is poorly understood. This study characterizes the genomic features and clinical outcomes of advanced pediatric MDS.
Methods
In this retrospective study, next‐generation sequencing was performed on 63 pediatric patients with advanced MDS, including 46 with MDS with excess blasts (MDS‐EB) and 17 with MDS‐EB in transformation (MDS‐EB‐T, 2016 WHO classification), to detect somatic and potential germline variants.
Results
Mutations in 53 genes were detected in 49 patients (77.8%), with a median of 2 variants per patient (range, 0–8). Alterations in the RAS/MAPK pathway were most common, occurring in 28 patients (44.4%). Monosomy 7 significantly co‐occurred with SETBP1 , ETV6 , and GATA2 mutations ( p < 0.01). Time‐dependent analyses showed HSCT improved 2‐year overall survival (OS, 42.6% vs. 84.5%, p = 0.003) and event‐free survival (EFS, 37.3% vs. 58.2%, p = 0.011). In multivariate analyses, HSCT was strongly associated with improved OS and EFS ( p < 0.01). PTPN11 mutation remained an independent predictor of poorer OS and EFS ( p < 0.05), and MDS‐EB‐T subtype independently predicted inferior EFS ( p < 0.05).
Conclusion
In advanced pediatric MDS, HSCT was associated with improved survival, whereas PTPN11 mutations emerged as an adverse prognostic factor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Tianjin Institute of Health Science, Tianjin, China.
ORCID-Profile: Chenmeng Liu, Xingchen Wang, Wenbin An, Xiaolan Li, Lipeng Liu, Wenyu Yang, Xiaofan Zhu
Förderung
- CAMS Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
Zitieren
APA
Liu, C., Wang, X., Chen, Y., Wan, Y., An, W., Li, X., Liu, L., Liu, F., Zhang, L., Zou, Y., Chen, X., Chen, Y., Guo, Y., Yang, W., & Zhu, X. (2026). Genomic Landscape and Clinical Outcomes of Advanced Pediatric Myelodysplastic Syndromes. European Journal of Haematology, 117(1), 235-244. https://doi.org/10.1111/ejh.70182
Vancouver
Liu C, Wang X, Chen Y, Wan Y, An W, Li X, et al. Genomic Landscape and Clinical Outcomes of Advanced Pediatric Myelodysplastic Syndromes. European Journal of Haematology. 2026;117(1):235-244. doi:10.1111/ejh.70182
BibTeX
@article{Liu2026,
author = {Liu, Chenmeng and Wang, Xingchen and Chen, Yunlong and Wan, Yang and An, Wenbin and Li, Xiaolan and Liu, Lipeng and Liu, Fang and Zhang, Li and Zou, Yao and Chen, Xiaojuan and Chen, Yumei and Guo, Ye and Yang, Wenyu and Zhu, Xiaofan},
title = {Genomic Landscape and Clinical Outcomes of Advanced Pediatric Myelodysplastic Syndromes},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {1},
pages = {235--244},
doi = {10.1111/ejh.70182}
}
EUVIMED